Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Maze Therapeutics, Inc.NASDAQ: MAZE
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items growth accelerates
Q1 FY2026 other non-cash items of $1.22M rose 55.2% year over year, ahead of the -85.1% change in trailing-twelve-month other non-cash items. Sequentially, it rose 111.1% from the prior quarter. Over 3 fiscal years it compounded at -32.0% a year.
Context
- Other non-cash items increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +55.2% holds above the trailing-twelve-month pace of -85.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 2.65M USD
- Year-over-year change
- -78.5%
- 3-year CAGR
- -32.0%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.65M | -78.5% |
| FY2024 | 2024-12-31 | 12.3M | +74.1% |
| FY2023 | 2023-12-31 | 7.07M | -16.0% |
| FY2022 | 2022-12-31 | 8.42M | — |
Other Non-Cash Items vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -85.1% is the 5th highest of 8, against a peer median of +112.0%.
- Other non-cash items amounts to 5.6% of revenue for MAZE, versus a peer median of 15.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €205.07M EUR | +121.4% | +245.4% | 4574.3% | |
| LTM Sep 2026 | $121.03M USD | +1589.7% | — | 18.6% | |
| LTM Jun 2026 | $37.79M USD | -205.6% | — | 3.7% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $31.89M USD | +131.2% | — | 33.1% |
| LTM Mar 2026 | $4.38M USD | -226.7% | — | 1.0% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $1.33M USD | -650.6% | — | 12.9% |
| LTM Mar 2026 | $1.12M USD | -85.1% | -32.0% | 5.6% | |
| LTM Mar 2026 | $144.11K USD | +112.0% | +15.7% | — | |
| Peer median (excluding MAZE) | — | +112.0% | +130.5% | 15.7% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.